Placebo effects in autism: Lessons from secretin

Journal of Developmental and Behavioral Pediatrics

Volumn 21, Issue 5, 2000, Pages 347-350

  Sandler, Adrian D ^a   Bodfish, James W ^b,c  

^a Olson Huff Ctr for Child Devmt   (United States)

^b Western Carolina Center   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SECRETIN;

ARTICLE; AUTISM; CHILD; HUMAN; PRESCHOOL CHILD; RESEARCH;

AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; HUMANS; PLACEBO EFFECT; RESEARCH; SECRETIN;

EID: 0034302910     PISSN: 0196206X     EISSN: 15367312     Source Type: Journal    
DOI: 10.1097/00004703-200010000-00005     Document Type: Article

References (19)

1. Sandler A, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW: Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 341:1801-1806. 1999
2. Shapiro AK, Shapiro E: The placebo: Is it much ado about nothing?, in Harrington A (ed): The Placebo Effect: An Interdisciplinary Exploration. Cambridge, MA, Harvard University Press, 1997, pp 13-14
3. The bottle of medicine (editorial). Br Med J 1:149, 1952
4. Harrington A (ed): The Placebo Effect: An Interdisciplinary Exploration. Cambridge, MA, Harvard University Press, 1997, p 7
5. Frank JD: Persuasion and Healing. Baltimore, MD, Johns Hopkins University Press, 1973
6. Shapiro AK. Latroplacebogenics. Int Pharmacopsychiatry 2:215-248,1969
7. Horwitz RI, Horwitz SM: Adherence to treatment and health outcomes. Arch Int Med 153:1863-1868, 1993
8. Kirsch I: Response expectancy as a determinant of experience and behavior. Am Psychol 40:1189-1202, 1985
9. Levine JD, Gordon NC, Fields HL: The mechanism of placebo analgesia. Lancet 2:654-657, 1978
10. Ader RA, Cohen N: Behaviorally conditioned immunosuppression. Psychosom Med 37:333-340, 1975
11. Spiro H: Clinical reflections on the placebo phenomenon, in Harrington A (ed): The Placebo Effect: An Interdisciplinary Exploration. Cambridge. MA. Harvard University Press, 1997, pp 37-55
12. Owley, Steele E, Corsello C, et al: A double-blind, placebo-controlled trial of secretin for the treatment of autistic disorder. Medscape Gen Med [serial online], October 6, 1999
13. Anderson L, Campbell M, Grega DM, Perry R, Small AM, Green WH: Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry 141:1195-1202, 1984
14. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL: A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50:441-447, 1993
15. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008, 1996
16. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633-641, 1998
17. Volkmar F, Cook EH Jr, Pomeroy J, Realmuto G, Tanguay P: Practice parameters for the assessment and treatment of children, adolescents and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 38(12 Suppl):32S-54S, 1999
18. Bristol M, et al: State of the science in autism: Report to the National Institutes of Health. J Autism Dev Disord 26:121-154, 1996
19. Sackett DL, Rosenberg WMC, Gray JAM: Evidence-based medicine: What it is and what is isn’t. Br Med J 312:71-75,1996